2. Safe Harbor Disclaimer
»
This presentation may contain forward-looking statements. Readers are cautioned
»
not to place undue reliance on forward-looking statements, which speak only as of
the date that they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and uncertainties that
could cause actual results and outcomes to be materially different. Risks and
uncertainties that may affect the future results of the Company include, but are not
limited to, the competitive environment, changes in government regulations,
changing relationships with customers, payers, suppliers and strategic partners and
other factors discussed in “Business” in Part I, Item 1, “Risk Factors” and
“Cautionary Statement for Purposes of the ‘Safe Harbor’ Provisions of the Private
Securities Litigation Reform Act of 1995” in Item I, Part 1A, “Legal Proceedings” in
Part I, Item 3, “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in Part II, Item 7 and “Quantitative and Qualitative
Disclosures About Market Risk” in Part II, Item 7A in the Quest Diagnostics 2007
Annual Report on Form 10-K and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” and “Quantitative and Qualitative
Disclosures About Market Risk” in the Company’s 2008 Quarterly Reports on Form
10-Q and other items throughout the Form 10-K and the Company’s 2008 Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K.
A copy of this presentation is available on
our website at www.questdiagnostics.com Patients Growth People
3. Who is Quest Diagnostics?
»
» Leader in Providing Healthcare Insights and Solutions
Comprehensive Diagnostic Testing
Routine ——» Esoteric
• Diagnose
• Monitor
• Predict
• Prevent
Advanced Information Technology Solutions
Improve Care and Efficiency
Facilitate Introduction of New Therapeutics
Clinical Trials Testing
Innovative Diagnostic Products
Enable Care Closer to the Patient
Risk Assessment Solutions to Life Insurance Industry
Touching Patients ~150 Million Times Each Year
Patients Growth People
4. The Leader in Diagnostic Testing
»
US Diagnostic Testing
» Market: >$45 B
$ in millions
Source: Washington G-2 Reports and company information
Patients Growth People
5. Consistently Strong Growth
»
#11 Fortune 500 Ranking: 10-year Total Shareholder Return
» $8
Dollars in Billions
$7 Revenue
$6 1999-2007
10 yr CAGR 18%
$5
$4
$3
$2
$1
0
1999 2000 2001 2002 2003 2004 2005 2006 2007
$3.50
EPS
$3.00 1999-2007
10 yr CAGR 25%
$2.50
$2.00
$1.50
$1.00
$0.50
$0.00
1999 2000 2001 2002 2003 2004 2005 2006 2007
Fortune Ranking based on years 1997-2006 Patients Growth People
6. Favorable Industry Trends
»
» Essential Healthcare Service
Growing and Aging Population
Innovations in Science & Medicine
Personal Interest in Health
Convergence of Information
• Genetic Predisposition
• Diagnostic Testing
• Diagnostic Imaging
• Information Technology
Influences >70% of Healthcare Decisions
Patients Growth People
7. Moving to Higher Growth,
Higher Margin Segments »
» 2000 Revenue 2007 Pro Forma Revenue
Total Revenue: $3.4 Billion Total Pro Forma Revenue: $7.0 Billion
Patients Growth People
8. Expanding Market Leadership
»
2000 2008
» Clinical Testing
Gene-based & Esoteric Testing
Employer Services
Anatomic Pathology Testing P
Risk Assessment Services -
Healthcare Information Technology -
Point of Care (Near Patient) Testing -
Clinical Trials Testing P P
International Market - P
Overall Market Leader/Niche Leadership
P Market Participant
Patients Growth People
9. Our Goals
»
» Undisputed World Leader in Diagnostic Testing,
Information and Services
Profitably Grow > Industry Rate
Expand Operating Income to 20%
Expand International Operations to ~10% of Revenues
Patients Growth People
10. Strategy to Drive Profitable Growth
»
» Sustainable Competitive Advantage
Deliver Superior Patient Experience
Continuously Drive Six Sigma Quality
Lead in Medical Innovation/Information
Leverage Unparalleled Assets & Capabilities
Expand Diagnostic Scope
Expand Geographic Reach
Patients Growth People
11. Providing Superior Patient Experience
»
» Patient Gold Standards
Prompt, Caring, Courteous Service
PSC Appointment Scheduling
Only Laboratory with Appointment Scheduling at PSC’s
Reduces Patient Wait Time
Improves Patient Convenience
Google Health Collaboration
Facilitate Patient-Physician Communications
Secure Electronic Access to Lab Results
Patients Growth People
12. Leading Medical Innovator
»
» Broadest Product and Service Offering
Multiple Channels to Access New Technology
Internal Development – Nichols Institute
Joint Development Relationships
Licensing/Distribution Relationships
Most Comprehensive Test Menu
Leader in Cancer, CVD & Infectious Disease Testing
Pioneer in Molecular Diagnostics, LC-MS/MS & Micro-array
Leading Experts for Medical Consultation
900 MDs & PhDs
>30 Academic Associates
Unmatched Medical & Technical Expertise
Patients Growth People
13. Most Comprehensive Test Menu
»
» Cancer Transplantation / Coag
LeumetaTM HLA FDA-registered lab
H/I Breast Recurrence Coag consultations
Cancer of Unknown Primary New Technology
Cardiovascular Disease XSenseTM
Infectious Disease ClarisureTM
HepaScoreTM Amino Acids by LC/MS
PhenoscriptTM LC-MS/MS
Chikungunya Personalized Medicine
Epstein Barr Virus
Patients Growth People
14. Enabling Personalized & Targeted Medicine
»
» Improving Patient Care
Enables More Appropriate Drug Therapy
Rituxan® Rituxan® Sensitivity (CD20)
Herceptin® Her2
Campath® Campath Sensitivity (CD2)
Irinotecan UGT1A1
Warfarin CYP450 2C9
Carbamazephine HLA - screens out certain Asian patients
Abacavir HLA - predisposition to hypersensitivity
Aspirin Monitor personal resistance levels
Tysabri Tysabri Antibody testing
Improves Disease Management
Leumeta™ CellSearch
Hepascore™
Reducing Medical Costs Patients Growth People
15. Unparalleled Assets and Capabilities
»
» Patients Physicians Hospitals
Health
Plans
Employers Pharma
Life
Insurers
Serving ½ US Physicians & Hospitals
Broadest Services Offering
Leading Esoteric Labs
POC Products
Connectivity with 125,000 Physicians
4,000 Logistics Vehicles & 25 Aircraft
2,100 Patient Service Centers
Nationwide Appointment Scheduling
1,000 Person Sales Force
800 Pathologists & Dermatopathologists
13,500 Phlebotomists & Paramedical
Professionals
Patients Growth People
16. Expanding Diagnostic Scope
Near Patient Testing »
» Opportunity to Improve Patient Care
Attractive Benefits For Hospitals,
Physician Offices & International
Markets
Enables More Timely And Effective
Decisions
Expanding Product Menu
Platform Technology
Results Integrated into Care360
Reducing Medical Costs
Patients Growth People
17. Expanding Geographic Reach
»
» Broadening Our Geographical Coverage
Clear Leadership in US….with Room to Grow
Leverage Existing Labs in Puerto Rico, Mexico, and UK
Increase Foreign Testing Sent to Nichols Institute
Exploit Point of Care Distribution Network in 130 Countries
Entering India – Serving Multiple Markets
Increasing Market Opportunity
Patients Growth People
18. India. . .An Untapped Opportunity
»
» 1 Billion People and Emerging Economic Power
300 Million People in Middle Class
Expanding Consumerism
Increased Incidence of Chronic Disease
Diabetes: 17% (among the highest in the world)
Hypertension: 51% of adults
Hyperlipidemia
Cancer: ~1 million new cases each year
Infectious diseases: 1000 deaths/day from Tuberculosis
Expanding Interest in Early Detection, Prevention & Treatment
Highly Fragmented Diagnostic Testing Market
Patients Growth People
19. Leverage Strong Brands and
Expertise in India Market »
»
• Physicians
• Hospitals
• Pharmaceutical Companies
• Life Insurers
Medical/Scientific Expertise and Operational Excellence
• World renowned scientists, • Six Sigma
pathologists and testing • Laboratory best practices
methods
Patients Growth People
21. Reducing Costs by $500 Million
»
» Leverage Lean Six Sigma to Improve Efficiency
Streamline Lab Operations
Optimize Logistics Routes
and PSC Resources
Improve Billing and Call
Center Operations
Leverage Purchasing
Capabilities
Maintain Service Levels
Patients Growth People
22. 2007 Full Year Results
»
» Decisive Actions and Bold Moves Restored Momentum
Revenues $6.7 billion
Operating Income 16.3%
EPS $2.84
Cash from Operations $927 million
Positioned for Sustained Revenue & Earnings Growth
Patients Growth People
23. 2008 / 2009 Focus
»
» Margin Expansion and Earnings Growth
Drive Top-Line Growth
Integrate AmeriPath
Reduce Costs by $500 Million
Expand International and Products Businesses
Excellence in Execution
Patients Growth People
24. Building on Strength
»
» Industry Leader in a Vital and Growing Industry
A History of Disciplined Growth
Track Record of Successfully Integrating Acquisitions
Strong Cash Generator
Proven Management Team
Uniquely Positioned with Unparalleled Assets &
Capabilities
Focused on Execution
Patients Growth People
